



ASX Announcement

12 July 2024

Completion of Share Consolidation

Sydney, Australia; 12 July 2024: Cambium Bio Limited (ASX:CMB) (**Company**) a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to advise that the consolidation of the Company's issued capital on a basis that every 100 shares be consolidated into 1 share, every 100 options be consolidated into 1 option, as approved at the general meeting of shareholders held 28 June 2024, is now complete.

The shares and options on issue post-consolidation are detailed in the following table:

Security	Post-Consolidation
Shares	11,931,006
Options over Shares	263,629

New holding statements have been dispatched to shareholders and option holders advising them of their holdings on a post-consolidation basis.

Normal settlement trading of securities on a consolidated basis will commence on Wednesday 12 July 2024 (ASX:CMB).

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.